What are TUDCA’s main drawbacks?

Last Updated:
References
1.^Ma H, Zeng M, Han Y, Yan H, Tang H, Sheng J, Hu H, Cheng L, Xie Q, Zhu Y, Chen G, Gao Z, Xie W, Wang J, Wu S, Wang G, Miao X, Fu X, Duan L, Xu J, Wei L, Shi G, Chen C, Chen M, Ning Q, Yao C, Jia JA multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.Medicine (Baltimore).(2016 Nov)
2.^Albanese A, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, Hardiman O, Rinaldi G, Vanacore N, Dickie B, TUDCA-ALS Study GroupTauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol.Front Neurol.(2022)
3.^Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese ATauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.Eur J Neurol.(2016 Jan)
4.^Larghi A, Crosignani A, Battezzati PM, De Valle G, Allocca M, Invernizzi P, Zuin M, Podda MUrsodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study.Aliment Pharmacol Ther.(1997 Apr)
5.^Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda MTauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study.Dig Dis Sci.(1996 Apr)
6.^Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein STauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women.Diabetes.(2010 Aug)
7.^Walsh LK, Restaino RM, Neuringer M, Manrique C, Padilla JAdministration of tauroursodeoxycholic acid prevents endothelial dysfunction caused by an oral glucose load.Clin Sci (Lond).(2016 Nov 1)
8.^Pan XL, Zhao L, Li L, Li AH, Ye J, Yang L, Xu KS, Hou XHEfficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial.J Huazhong Univ Sci Technolog Med Sci.(2013-Apr)
9.^Zucchi E, Musazzi UM, Fedele G, Martinelli I, Gianferrari G, Simonini C, Fini N, Ghezzi A, Caputo M, Sette E, Vacchiano V, Zinno L, Anceschi P, Canali E, Vinceti M, Ferro S, Mandrioli J, ERRALS study groupEffect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study.EClinicalMedicine.(2023 Nov)
10.^Lombardo FL, Spila Alegiani S, Mayer F, Cipriani M, Lo Giudice M, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, Hardiman O, Nicolini G, Vanacore N, Dickie B, Albanese A, Puopolo M, TUDCA-ALS Study GroupA randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.Trials.(2023 Dec 5)
11.^da Silva JA Jr, Figueiredo LS, Chaves JO, Oliveira KM, Carneiro EM, Abreu PA, Ribeiro RAEffects of tauroursodeoxycholic acid on glucose homeostasis: Potential binding of this bile acid with the insulin receptor.Life Sci.(2021 Nov 15)
13.^Feng Y, Li Q, Ou G, Yang M, Du LBile acid sequestrants: a review of mechanism and design.J Pharm Pharmacol.(2021 Jun 8)
14.^Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OBEvolving landscape in the management of transthyretin amyloidosis.Ann Med.(2015)